Clinical Trial Update: Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment [Phase 2, Phase 3]

View source ↗

Summary

A multinational Phase 2/3 trial is studying Brentuximab Vedotin as initial therapy for newly diagnosed classical Hodgkin lymphoma in Chinese children, adolescen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Children's Cancer Group, China | Conditions: Classical Hodgkin Lymphoma, Child | Phase 2, Phase 3 | Status: RECRUITING